References
- Ezaki K. Cylokinc therapy for hematological malignancies. International Journal of Hematology 1996; 65(1)17–-29
- Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yoknmaku S, Nakayama S, Yoshida Y, Miura A B, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New England Journal of Medicine 1990; 323(13)871–-877
- Miyauchi J, Kelleher C A, Wang C, Minkin S, McCulloch E A. Growth factor influence the sensitivity of leukemic stem cells to cytokine urabinoside in culture. Blood 1989; 73(5)1272–-1278
- Bühner T, Hiddemann W, Wörmann B, Zühlsdorf M, Rott-mann R, Innig G, Maschmeier G, Ludwig W D, Sauerland M C, Heinecke A. Hematopoietic growth factors in acute myeloid leukemia : supportive and priming effects. Seminars in Oncology 1997; 24(1)124–-131
- Huhmann I M, Watzke H H, Geissler K, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitter-bauer G, Schwarzinger I, Kalhs P, Hass O A, Lechner K. FLAG (fludarabine. cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Annals of Hematology 1996; 73(6)265–-271
- Bai A, Kojima H, Hori M, Nara N, Komeno T, Hasegawa Y, Ninomiya H, Abe T, Nagasawa T. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Experimental Hematology 1999; 27(2)259–-265
- Hiddemann W, Kiehl M, Ziihlsdorf M, Bussemann C, Schl-eye E, Wormann B, Buchner T. Granulocyte-macroph-age colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Seminars in Oncology 1992; 19(2 Suppl 4)31–-37
- Pierce J H, Marco E D, Cox G W, Lombardi D, Ruggiero M, Varesio L, Wang L M, Choudhury G G, Sakaguchi A Y, Fiore P PD, Aaronson L M. Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. Proceedings of theNational Academy of Sciences of the United States of America 1990; 87(15)5613–-5617
- Bennett J M, Catovsky D C, Daniel M T, Flandrin G, Gallon D AG, Gralnick H R, Sultan C. Proposal for classification of the myelodysplastic syndromes. British Journal of Haematology 1982; 51(2)189–-199
- Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S, Yoshida M, Aoyagi M, Nakamura Y, Enokihara H, Tanaka K, Naka-zawa K, Shishido H. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study. Leukemia 1995; 9(1)10–-14
- Philpott N J, Turner A JC, Scopes J, Westby M, Marsh J CW, Gordon-Smith E C, Dalgleish A G, Gibson F M. The use of 7-amino actinomycin D in identifying apoptosis : simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87(6)2244–-2251
- Kitano K, Kobayashi H, Maekawa H, Miyabayashi H, Furuta S. Treatment of acute monoblastic leukemia by combination of recombinant human macrophage colony-stimulating factor and low dose ara-C. British Journal of Haematology 1993; 85(1)176–-178
- Sebban C, Archimbaud E, Coiffier B, Guyotat D, Treille-Ritouet D, Maupas J, Fiere D. Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer 1988; 61(2)227–-231